Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Giuseppe Remuzzi, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy

*CORRESPONDENCE Baihai Su, ⊠ subaihai@scu.edu.cn Ruoxi Liao, ⊠ lrx-wch@foxmail.com

¹These authors have contributed equally to this work and share first authorship

RECEIVED 22 July 2024 ACCEPTED 14 October 2024 PUBLISHED 05 November 2024

CITATION

Luo X, Zhou W, Wan D, Peng J, Liao R and Su B (2024) Corrigendum: Association between amoxicillin administration and outcomes in critically ill patients with acute kidney injury. *Front. Pharmacol.* 15:1468612. doi: 10.3389/fphar.2024.1468612

COPYRIGHT

© 2024 Luo, Zhou, Wan, Peng, Liao and Su. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Association between amoxicillin administration and outcomes in critically ill patients with acute kidney injury

Xinyao Luo^{1†}, Weijian Zhou^{1†}, Dingyuan Wan², Jing Peng¹, Ruoxi Liao^{1*} and Baihai Su^{1*}

¹Department of Nephrology, Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, China, ²Department of Intensive Care Medicine, West China Hospital, Sichuan University, Chengdu, China

KEYWORDS

acute kidney injury, amoxicillin, intensive care unit, mortality, acute kidney disease

A Corrigendum on

Association between amoxicillin administration and outcomes in critically ill patients with acute kidney injury

by Luo X, Zhou W, Wan D, Peng J, Liao R and Su B (2024). Front. Pharmacol. 15:1409654. doi: 10. 3389/fphar.2024.1409654

In the published article, there was an error in Figure 2 as published. Figure 2 contains superfluous elements. The corrected Figure 2 and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Out	come		HR/MD	(95%	CI) F	value				
	day mortality			1 /0	<u>.</u>					
Crude		н	R 0.54 (0	.42.0.	70)	< 0.001		⊢ •−−1	1	
Mult	tivariable		R 0.54 (0			< 0.001		⊢ •−−1		
PSN	Λ		R 0.44 (0			< 0.001		— •—		
IPT\	N		R 0.50 (0			<0.001		⊢ •──1		
90-0	day mortality									
Cruc	de	н	R 0.68 (0	.56,0.	83)	< 0.001		├ ─◆	-	
Mult	tivariable	н	R 0.64 (0	.52,0.	77)	< 0.001		⊢	(
PSN			R 0.53 (0			< 0.001		. ⊢_		
PT			R 0.61 (0	.49,0.	75)	<0.001		⊢ •−−1		
	ite kidney dis									
Cruc			R 0.46 (0			< 0.001		⊢ ♦──1		
	tivariable		R 0.49 (0			<0.001		⊢ •−−1		
PSN			R 0.52 (0			< 0.001		H•	1	
PT			R 0.49 (0	.46,0.	52)	< 0.001		I+I		
	igth of ICU sta	-								
Line			-0.24 (-0	0.61,0.	13)	0.21				
	igth of hospita	-		45.0	75	-0.004				
Line	ar	IVI	D 1.95 (1	.15,2.	(5)	< 0.001		1.00		
					С		0	1	1	1
					С		0	1 0.5	1	1
0-					C		0	1 0.5	1	1
_					1.00	1	0	0.5	1	1
_				Paliter.	1.00	1	0	0.5	1	1
5-					1.00		0	0.5	1	1
5-					1.00		0	0.5		=
5- 0-	30-day mortality	y A	moxicillin		1.00		1 O		I 1 Amoxic	=
5- 0-	And an and a second second	y A	- Unused		1.00	90-da	y mortal		Amoxic	=
5- 0- 5-	After PSM	y A		Landon Landon Landon	1.00 0.75 0.50 0.25	90-da Af	ly mortal ter PSM		Amoxic	illin used
5- 0- 5-	After PSM p < 0.0001	,	- Unused	_	1.00-	90-da Af p =	y mortal ter PSM =0.00012	ity	Amoxic + Uni + Use	sillin used ed
5- 0- 5-	After PSM p < 0.0001	20	- Unused		1.00 0.75 0.50 0.25	90-da Af	ly mortal ter PSM	ity 50	Amoxic + Uni	illin used
5- 5- 0	After PSM p < 0.0001 0 10	,	- Unused	_	1.00 0.75 0.50 0.25	90-da Af p = 0	ter PSM =0.00012 25	ity	Amoxic + Uni + Use	sillin used ed
5- 5- 0	After PSM p < 0.0001	20	- Unused	_	1.00 0.75 0.50 0.25	90-da Af p =	ter PSM =0.00012 25	ity 50	Amoxic + Uni + Use	sillin used ed
5- 0(After PSM p < 0.0001) 10 7 umber at risk	20	Unused	_	1.00 0.75 0.50 0.25 0.25	90-da Af p = 0	ter PSM =0.00012 25	ity 50	Amoxic + Uni + Use	sillin used ed

FIGURE 2

The association between amoxicillin administration and clinical outcomes in patients with AKI. (A) Association between amoxicillin administration and clinical outcomes. Four different methods were used to address the associations: 1) univariable Cox regression, 2) multivariable Cox regression, 3) propensity score matching, and 4) inverse propensity weighted modeling. (B) Kaplan–Meier survival curves of the amoxicillin group and non-amoxicillin group after PSM for 30-day mortality. (C) Kaplan–Meier survival curves of the amoxicillin group and non-amoxicillin group after PSM for 30-day mortality. Notes: HRs (95% CIs) were derived from Cox proportional hazards regression models. Covariates were adjusted as in the model II. The MDs (95% CIs) were derived from linear regression models. Covariates were adjusted as in the model II. Abbreviations: HR, hazard ratio; MD mean difference; PSM, propensity score matching; IPTW, inverse probability of treatment weighting; ICU, intensive care unit.